COVID-19 Program

About ExeVir

ExeVir is a private, clinical-stage biotech leveraging a proprietary VHH (single-domain antibody) platform to develop multi-specific antibody therapies against infectious diseases. The company has demonstrated rapid development capabilities, advancing its first candidate from research to clinical trials in under a year. Backed by a strong international investor syndicate and strategic research partnerships, ExeVir is building a pipeline initially targeting COVID-19 and dengue, with the platform holding promise for broader applications in immunology and oncology.

About Arisan Therapeutics

Arisan Therapeutics is a private, preclinical-stage biotech focused on developing small-molecule antiviral drugs for infectious diseases. The company is targeting high-burden viral infections such as COVID-19 and influenza, operating in a critical and dynamic segment of the pharmaceutical market. As a young company, it is in the early stages of building its pipeline and technology platform, positioning itself to address unmet medical needs in virology. Its success will depend on advancing its research, securing funding, and navigating the complex competitive and regulatory landscape of antiviral drug development.

About Sixty Degrees Pharmaceuticals

Sixty Degrees Pharmaceuticals is a U.S.-based biotech targeting major global infectious diseases like malaria, dengue, and COVID-19. The company appears to be advancing a portfolio of small-molecule therapeutics, with a recent commercial launch indicated for malaria prevention. Its strategy involves both product development and commercialization to serve travelers and endemic regions, positioning itself at a critical intersection of public health need and market opportunity.

Therapeutic Areas

Other COVID-19 Drugs